Aerie Pharmaceuticals Announces Phase 3 Topline Results For Netarsudil Ophthalmic Solution 0.02% Clinical Trial In Japan; Netarsudil Ophthalmic Solution 0.02% Once Daily Demonstrated Superiority To Ripasudil 0.4% Twice Daily